Table 1.
LPS-induced Inhibition of HIV Replication in MDM Is Mediated by the Release of Soluble Factors
| Culture | Supernatant added | Polymixin | HIV-1 p24 Ag release | |||||
|---|---|---|---|---|---|---|---|---|
| Day 4 | Day 7 | |||||||
| pg/ml | ||||||||
| MDM+HIV-1 | Nil | − | 3,209 | 12,616 | ||||
| MDM+HIV-1 | Nil | + | 3,620 | 13,917 | ||||
| MDM+HIV-1+ 1LPS | Nil | − | 108 | 992 | ||||
| MDM+HIV-1+ 1LPS | Nil | + | 2,953 | 12,408 | ||||
| MDM+HIV-1 | Untreated MØ | + | 3,048 | 13,726 | ||||
| MDM+HIV-1 | LPS-treated MØ | + | 100 | 300 | ||||
MDM from healthy donors were infected in vitro with HIV-1, in the presence of LPS (1 μg/m), LPS-conditioned supernatants (100% vol/ vol), or polymixin B sulfate (15 μg/ml). Supernatants from infected cultures were harvested at different timepoints, and assayed by ELISA for p24 Ag secretion.